ANTX Sets June 3 Shareholder Meeting to Elect Directors, Ratify Auditor
Filing Summary
🧾 What This Document Is
This is a proxy statement (DEF 14A) for AN2 Therapeutics. Think of it as the official "agenda packet" for the company's annual shareholder meeting. Its job is to give you all the information you need to vote on key decisions, even if you can't attend in person.
- Meeting Date: June 3, 2026, at 8:00 a.m. Pacific Time.
- Location: Residence Inn, 555 Glenwood Avenue, Menlo Park, California.
- Record Date: April 15, 2026. You must own shares by this date to vote.
- How to Vote: You can vote online, by phone, or by mail. The company will mail instructions around April 22, 2026.
👉 Why it matters: This document is your toolkit for having a say in the company's leadership and oversight. Your vote directly influences who runs the board and who audits the books.
🏢 What The Company Does
In simple terms, AN2 Therapeutics is a biotech company focused on developing new medicines for serious infectious diseases, like those caused by Mycobacterium avium complex (MAC).
- Industry: Biopharmaceuticals (Drug Development)
- Focus: They are a "clinical-stage" company, meaning their main drug candidates are still being tested in people and are not yet approved or sold.
- Ticker Symbol: ANTX (listed on Nasdaq)
👥 The People in Charge: Board & Leadership
This section covers who is being elected and who is already running things.
🗳️ Proposal 1: Elect Three Directors
You are voting to elect three people to the Board of Directors. They will serve until 2029. The Board recommends voting FOR each one.
| Nominee | Age | Why They're Qualified |
|---|---|---|
| Kabeer Aziz | 36 | Partner at a life sciences fund focused on global health & infectious diseases. |
| Gilbert Lynn Marks, M.D. | 68 | Former senior pharma executive (GSK), expert in infectious diseases, advises U.S. government panels. |
| Rob Readnour, Ph.D. | 62 | Venture capitalist, former senior R&D director at Elanco Animal Health with 30+ years in product development. |
👤 Current Executive Team
- Eric Easom (58): President, CEO, and Board Chair. Co-founder.
- Lucy Day (67): Chief Financial Officer.
- Sanjay Chanda, Ph.D. (61): Chief Development Officer.
- Joshua Eizen (49): Chief Legal Officer & Chief Operating Officer.
🏛️ Board Committees
The Board has three key groups, each with a specific job:
- Audit Committee: Oversees financial reporting and the accounting firm. (Members: Wong, Martin, Zakrzewski)
- Compensation Committee: Decides pay for top executives. (Members: Aziz, FitzPatrick, Spigelman)
- Nominating & Governance Committee: Finds new directors and oversees board rules. (Members: Readnour, Marks)
💰 Executive Compensation
This is how much the top bosses were paid in 2025. Their total pay is a mix of salary, cash bonuses, and long-term stock awards (which are only valuable if the company's stock price goes up).
| Named Executive Officer | 2025 Salary | 2025 Bonus (Cash) | 2025 Value of Stock/Option Awards | Total 2025 Compensation |
|---|---|---|---|---|
| Eric Easom (CEO) | $603,750 | $332,063 | $439,672 | $1,382,985 |
| Josh Eizen (CLO/COO) | $450,000 | $180,000 | $177,080 | $807,080 |
| Lucy Day (CFO) | $447,200 | $178,880 | $140,756 | $774,336 |
👉 Why it matters: A large portion of pay is tied to performance (bonuses) and long-term stock incentives. This is meant to align the executives' interests with yours as a shareholder. For 2025, the board awarded 100% of the target bonus for hitting corporate goals.
🗳️ Proposal 2: Ratify the Auditor
You are voting to approve the selection of PricewaterhouseCoopers LLP (PwC) as the company's independent accounting firm for 2026. The Board recommends voting FOR. This is a standard, "routine" item to ensure the financial check-up is trusted.
⚖️ Big Picture: Strengths & Risks
👍 Strengths:
- Expert Board: The director nominees have deep experience in infectious diseases, pharma R&D, and biotech finance.
- Aligned Pay: Executive pay is heavily tied to company performance and stock price.
- Governance Checks: The board has independent committees (Audit, Comp) and a lead independent director to oversee the CEO/Chair.
⚠️ Risks & Considerations:
- Clinical Stage Company: AN2 is not yet profitable. Its future depends heavily on the success of its drug development pipeline, which is inherently risky.
- Cash Burn: As a development-stage biotech, the company spends money on research without revenue from product sales. It needs to manage its cash carefully.
- Staggered Board: The board is divided into classes, which makes it harder for shareholders to change the board's composition quickly in a single year.
🧠 The Analogy
Voting on this proxy is like being a part-owner of a professional sports team. You're not making the day-to-day coaching decisions, but you get to vote on who sits on the ownership committee (the Board) that hires the general manager (the CEO), and you approve the outside auditors who verify the team's finances. The star players' (executives') contracts are also public, so you can see if their pay matches the team's performance.
🧩 Final Takeaway
This annual meeting is about shareholder voice in governance. You are asked to renew the board's mandate by electing experienced directors and to approve the financial watchdog (PwC). The executive pay details show a structure meant to reward long-term growth, which is crucial for a clinical-stage biotech like AN2 Therapeutics.